Allogene Therapeutics Expands ALPHA3 Study to South Korea and Australia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2026
0mins
Should l Buy ALLO?
Allogene Therapeutics announced that regulatory authorities in South Korea and Australia have cleared the Company to expand its pivotal Phase 2 ALPHA3 study evaluating cemacabtagene ansegedleucel in first-line consolidation treatment for patients with large B-cell lymphoma, LBCL. The study, currently enrolling across more than 60 sites in North America, will expand to over 80 global sites with the addition of South Korea and Australia. This growing trial footprint reflects strong interest in ALPHA3 from clinical trial sites. "Expanding into South Korea and Australia allows us to leverage regions with established clinical research infrastructure and experienced investigators," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "These countries provide high-quality trial environments and efficient healthcare delivery systems. These regulatory approvals, follow our recent interim futility analysis, and we expect this expansion to support the continued enrollment and global development of cema-cel."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALLO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALLO
Wall Street analysts forecast ALLO stock price to rise
11 Analyst Rating
10 Buy
0 Hold
1 Sell
Strong Buy
Current: 2.270
Low
5.00
Averages
8.50
High
14.00
Current: 2.270
Low
5.00
Averages
8.50
High
14.00
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Allogene Showcases CAR T Therapy Potential at AACR Meeting
- Preclinical Evaluation: Allogene presented its preclinical evaluation of BCMA/CD70 dual-targeting CAR T cells for high-risk multiple myeloma at the AACR meeting, indicating potential new treatment options for patients in cancer therapy.
- Technology Expansion: The company plans to extend its Dagger® technology into autoimmune diseases, utilizing a gene-edited dual-targeting CAR T approach aimed at reducing the need for chemotherapy-based lymphodepletion, thereby enhancing treatment durability and safety.
- Future Outlook: Allogene's CAR T therapy aims to enhance accessibility through on-demand availability, safety, and simplicity, potentially transforming the treatment landscape for cancer and autoimmune diseases in the future.
- Industry Leadership: Allogene is positioned as a leader in the evolution of autologous cell therapies, leveraging extensive experience in hematologic and solid tumors to address the growing patient demand and drive advancements in biologic manufacturing scale.
See More
Allogene Publishes Preclinical Data for ALLO-329 in Autoimmune Diseases
- Dual Targeting Approach: ALLO-329 demonstrates significant enhancement of CAR T cell expansion and persistence by simultaneously targeting CD19+ B cells and CD70+ T cells in autoimmune disease models, indicating its potential in treating conditions like systemic lupus erythematosus.
- Clinical Trial Progress: The ongoing Phase 1 RESOLUTION trial is actively enrolling patients, with initial data expected in June 2026, showcasing the product's prospects across various autoimmune diseases.
- FDA Fast Track Designation: ALLO-329 has received three Fast Track Designations from the FDA for the treatment of lupus, myositis, and scleroderma, highlighting its importance and potential market opportunities in clinical development.
- Manufacturing Advantages: The development of ALLO-329 integrates CRISPR technology and Dagger® technology, aiming to reduce or eliminate the need for conventional lymphodepletion, thereby enhancing treatment accessibility and patient tolerability, which could become a critical competitive differentiator in the cell therapy space.
See More
Allogene Therapeutics Prices $175M Public Offering of Common Stock
- Offering Size: Allogene Therapeutics has priced an underwritten public offering of 87.5 million shares at $2.00 per share, expecting gross proceeds of $175 million, which will support clinical trials and R&D initiatives.
- Underwriter Option: The underwriters have a 30-day option to purchase an additional 13.13 million shares, providing flexibility that could enhance the company's liquidity and market confidence.
- Use of Proceeds: The net proceeds from the offering will fund general corporate purposes, including clinical trials, R&D, administrative costs, and capital expenditures, thereby laying a foundation for the company's long-term growth.
- Market Reaction: Following the public offering announcement, Allogene's stock price dropped over 4% during after-market trading on Tuesday, reflecting a cautious market sentiment that may impact investor confidence.
See More
Allogene Therapeutics Prices $175 Million Public Offering
- Offering Size and Pricing: Allogene Therapeutics has priced its public offering at $2.00 per share for a total of 87.5 million shares, raising $175 million, with the offering expected to close on April 16, 2026, indicating the company's ability to access capital markets effectively.
- Underwriter Selection: Goldman Sachs, Jefferies, and TD Cowen are acting as joint bookrunners for the offering, reflecting the company's professionalism in selecting underwriters and enhancing investor confidence in the offering's success.
- Use of Proceeds: The net proceeds from this offering will be allocated to clinical trials, research and development, general and administrative expenses, and capital expenditures, underscoring the company's commitment to advancing its allogenic CAR-T therapies for autoimmune and cancer indications.
- Stock Price Fluctuations: Allogene's stock has traded between $0.86 and $4.46 over the past year, closing at $2.28, down 25.37% from the previous day, indicating market caution regarding the company's future prospects.
See More
Allogene Therapeutics Prices Public Offering at $2.00 per Share
- Offering Size: Allogene Therapeutics announced a public offering of 87.5 million shares at $2.00 per share, expecting gross proceeds of $175 million, which will support clinical trials and R&D, enhancing its competitive position in the biotech sector.
- Underwriting Arrangement: The offering is led by Goldman Sachs, Jefferies, and TD Cowen as joint bookrunners, with Piper Sandler and William Blair also involved, indicating strong market confidence in Allogene and potentially attracting more investor interest in its future developments.
- Additional Share Option: Allogene granted underwriters a 30-day option to purchase up to 13.125 million additional shares, providing a flexible financing strategy that could yield extra funds to meet future R&D needs.
- Strategic Use of Proceeds: The net proceeds will be allocated for general corporate purposes, including clinical trials, R&D, administrative expenses, and capital expenditures, reflecting Allogene's proactive approach to achieving its long-term goals in cancer and autoimmune disease treatment.
See More
Amazon Nears Globalstar Acquisition, Stock Soars
- Amazon Acquisition Talks: Globalstar shares surged 19% following reports that Amazon is in advanced negotiations to acquire the company, which could accelerate its low-Earth orbit satellite strategy and enhance competition with SpaceX's Starlink network.
- Bloom Energy Partnership Expansion: Bloom Energy's stock rose 15% after Oracle expanded its partnership to procure up to 2.8 GW of fuel cell capacity for AI data centers, with an initial 1.2 GW contracted and deployment expected by 2027, highlighting the growing demand for reliable energy solutions.
- Credo Technology Acquisition: Credo Technology shares jumped 9% after announcing a $750 million cash-and-stock deal to acquire DustPhotonics, strengthening its position in high-speed optical connectivity, with the acquisition expected to enhance its optical transceiver portfolio and positively impact non-GAAP EPS by FY2027.
- Allogene Therapeutics Financing Plan: Allogene Therapeutics shares fell 6% after announcing a $175 million underwritten public offering, with proceeds aimed at funding clinical trials, R&D, and operational expenses, indicating a pressing need for capital amid ongoing development efforts.
See More
Allogene Showcases CAR T Therapy Potential at AACR Meeting
- Preclinical Evaluation: Allogene presented its preclinical evaluation of BCMA/CD70 dual-targeting CAR T cells for high-risk multiple myeloma at the AACR meeting, indicating potential new treatment options for patients in cancer therapy.
- Technology Expansion: The company plans to extend its Dagger® technology into autoimmune diseases, utilizing a gene-edited dual-targeting CAR T approach aimed at reducing the need for chemotherapy-based lymphodepletion, thereby enhancing treatment durability and safety.
- Future Outlook: Allogene's CAR T therapy aims to enhance accessibility through on-demand availability, safety, and simplicity, potentially transforming the treatment landscape for cancer and autoimmune diseases in the future.
- Industry Leadership: Allogene is positioned as a leader in the evolution of autologous cell therapies, leveraging extensive experience in hematologic and solid tumors to address the growing patient demand and drive advancements in biologic manufacturing scale.
See More
Allogene Publishes Preclinical Data for ALLO-329 in Autoimmune Diseases
- Dual Targeting Approach: ALLO-329 demonstrates significant enhancement of CAR T cell expansion and persistence by simultaneously targeting CD19+ B cells and CD70+ T cells in autoimmune disease models, indicating its potential in treating conditions like systemic lupus erythematosus.
- Clinical Trial Progress: The ongoing Phase 1 RESOLUTION trial is actively enrolling patients, with initial data expected in June 2026, showcasing the product's prospects across various autoimmune diseases.
- FDA Fast Track Designation: ALLO-329 has received three Fast Track Designations from the FDA for the treatment of lupus, myositis, and scleroderma, highlighting its importance and potential market opportunities in clinical development.
- Manufacturing Advantages: The development of ALLO-329 integrates CRISPR technology and Dagger® technology, aiming to reduce or eliminate the need for conventional lymphodepletion, thereby enhancing treatment accessibility and patient tolerability, which could become a critical competitive differentiator in the cell therapy space.
See More
Allogene Therapeutics Prices $175M Public Offering of Common Stock
- Offering Size: Allogene Therapeutics has priced an underwritten public offering of 87.5 million shares at $2.00 per share, expecting gross proceeds of $175 million, which will support clinical trials and R&D initiatives.
- Underwriter Option: The underwriters have a 30-day option to purchase an additional 13.13 million shares, providing flexibility that could enhance the company's liquidity and market confidence.
- Use of Proceeds: The net proceeds from the offering will fund general corporate purposes, including clinical trials, R&D, administrative costs, and capital expenditures, thereby laying a foundation for the company's long-term growth.
- Market Reaction: Following the public offering announcement, Allogene's stock price dropped over 4% during after-market trading on Tuesday, reflecting a cautious market sentiment that may impact investor confidence.
See More
Allogene Therapeutics Prices $175 Million Public Offering
- Offering Size and Pricing: Allogene Therapeutics has priced its public offering at $2.00 per share for a total of 87.5 million shares, raising $175 million, with the offering expected to close on April 16, 2026, indicating the company's ability to access capital markets effectively.
- Underwriter Selection: Goldman Sachs, Jefferies, and TD Cowen are acting as joint bookrunners for the offering, reflecting the company's professionalism in selecting underwriters and enhancing investor confidence in the offering's success.
- Use of Proceeds: The net proceeds from this offering will be allocated to clinical trials, research and development, general and administrative expenses, and capital expenditures, underscoring the company's commitment to advancing its allogenic CAR-T therapies for autoimmune and cancer indications.
- Stock Price Fluctuations: Allogene's stock has traded between $0.86 and $4.46 over the past year, closing at $2.28, down 25.37% from the previous day, indicating market caution regarding the company's future prospects.
See More
Allogene Therapeutics Prices Public Offering at $2.00 per Share
- Offering Size: Allogene Therapeutics announced a public offering of 87.5 million shares at $2.00 per share, expecting gross proceeds of $175 million, which will support clinical trials and R&D, enhancing its competitive position in the biotech sector.
- Underwriting Arrangement: The offering is led by Goldman Sachs, Jefferies, and TD Cowen as joint bookrunners, with Piper Sandler and William Blair also involved, indicating strong market confidence in Allogene and potentially attracting more investor interest in its future developments.
- Additional Share Option: Allogene granted underwriters a 30-day option to purchase up to 13.125 million additional shares, providing a flexible financing strategy that could yield extra funds to meet future R&D needs.
- Strategic Use of Proceeds: The net proceeds will be allocated for general corporate purposes, including clinical trials, R&D, administrative expenses, and capital expenditures, reflecting Allogene's proactive approach to achieving its long-term goals in cancer and autoimmune disease treatment.
See More
Amazon Nears Globalstar Acquisition, Stock Soars
- Amazon Acquisition Talks: Globalstar shares surged 19% following reports that Amazon is in advanced negotiations to acquire the company, which could accelerate its low-Earth orbit satellite strategy and enhance competition with SpaceX's Starlink network.
- Bloom Energy Partnership Expansion: Bloom Energy's stock rose 15% after Oracle expanded its partnership to procure up to 2.8 GW of fuel cell capacity for AI data centers, with an initial 1.2 GW contracted and deployment expected by 2027, highlighting the growing demand for reliable energy solutions.
- Credo Technology Acquisition: Credo Technology shares jumped 9% after announcing a $750 million cash-and-stock deal to acquire DustPhotonics, strengthening its position in high-speed optical connectivity, with the acquisition expected to enhance its optical transceiver portfolio and positively impact non-GAAP EPS by FY2027.
- Allogene Therapeutics Financing Plan: Allogene Therapeutics shares fell 6% after announcing a $175 million underwritten public offering, with proceeds aimed at funding clinical trials, R&D, and operational expenses, indicating a pressing need for capital amid ongoing development efforts.
See More
